

United States Influenza Vaccines Market Size, Industry Trends, Share, Size, Growth, Opportunity and Forecast 2023-2031

<https://marketpublishers.com/r/U5B4B0F721A2EN.html>

Date: March 2023

Pages: 220

Price: US\$ 1,990.00 (Single User License)

ID: U5B4B0F721A2EN

Abstracts

The influenza vaccines market in the United States was valued at US\$ 3,962 billion in 2022 and is expected to reach US\$ 8,347 billion by 2031, registering a CAGR of 8.6% during the forecast period.

Rapid market expansion is primarily due to increased research and development, the introduction of quadrivalent influenza vaccines, the aging population, and vaccine awareness. In addition, expanded recommendations from government and advisory bodies to get influenza vaccines are driving market growth in the United States.

Influenza is the second leading cause of death from vaccine-preventable disease in the United States after COVID-19. Rates of seasonal influenza infection are highest in children, but the risks for complications, hospitalizations, and deaths are higher in adults 65 years of age and older, children younger than 5 years, pregnant women, and people of any age with conditions that place them at increased risk for influenza complications.

The report on the influenza vaccines market in the United States is a comprehensive study and presentation of drivers, restraints, opportunities, demand, market size, forecasts, and trends in the influenza vaccines market in the United States during 2018-2031. In addition, the report is a collective presentation of primary and secondary research findings.

Key Market Developments

The United States continues to be the world's largest influenza vaccines market

Demand for influenza vaccines is expected to increase over the forecast period due to the pandemic COVID -19

Moderna Announces Interim Phase 3 Safety and Immunogenicity Results for mRNA-1010, A Seasonal Influenza Vaccine Candidate

Novavax announces initiation of Phase 2 study for COVID-19 influenza combination vaccine and stand-alone influenza vaccine candidate

GSK and CureVac advance mRNA COVID-19 and influenza vaccine candidates

Seqirus receives a government contract to develop 2 influenza vaccines

This Well-Versed and Comprehensive United States Influenza Vaccines Market Research Report 2023 is Divided into 20 Chapters:

Chapter 1 contains a brief description of the market under study

Chapter 2 describes the research methodology of the study

Chapter 3 identifies key trends and prospects for the U.S. influenza vaccine market and draws key conclusions

Chapter 4 discusses the market scenario for influenza vaccines in the United States in terms of historical market values and projections through 2031

Chapter 5 analysis of adults and children in the United States vaccinated with influenza vaccines and projection through 2031

Chapter 6 highlights key market dynamics in the U.S. influenza vaccine market, including factors driving the market, prevailing barriers, potential opportunities, and future trends. This section also includes an analysis of the impact of the driving and restraining factors

Chapter 7 offers comprehensive insights into the latest pricing trends and analysis of the U.S. influenza vaccine market

Chapter 8 includes a comprehensive analysis of influenza vaccine production,

supply, and distribution in the United States (by company)

Chapter 9 provides a complete overview of influenza vaccine distribution and demand in the United States

Chapter 10 investigates the effectiveness of influenza vaccines in the United States

Chapter 11 thorough evaluation of rapid diagnostic tests for influenza management

Chapter 12 carefully evaluates the distribution channel and technique of influenza vaccination in the United States

Chapter 13 characteristics of reimbursement structures in the influenza vaccine market in the united states

Chapter 14 detailed insights into the legal framework of the U.S. influenza vaccine market

Chapter 15 tracks competitive developments, approaches, recent industry developments, and mergers and acquisitions, collaboration, distribution, exclusivity, and licensing agreements.

Chapter 16 an informative study was conducted on promising influenza vaccines in clinical development.

Chapter 17 analyses recent clinical trials of the influenza vaccine

Chapter 18 and 19 provides the industry landscape and detailed profiles of key and promising companies operating in the influenza vaccine market in the United States. The companies have been profiled based on their key facts, business description, products and services, current vaccine portfolio, promising vaccines in clinical development, platform technology, and key developments.

Chapter 20, i.e. the appendix contains a brief overview of the company, a glossary, contact information, and the disclaimer section.

Key and Emerging Players in the U.S. Influenza Vaccines Market are Listed Below:

Sanofi Pasteur

GlaxoSmithKline (GSK)

Seqirus (CSL Limited)

AstraZeneca

Novavax

Medicago

Moderna Inc

Pneumagen

Daiichi-Sankyo

Altimune

FluGen

Imutex

EpiVax, Inc

Versatope Therapeutics, Inc

BiondVax Pharmaceuticals Ltd.

The Most Important Questions are Answered in this Current 2023 Report:

What is the current size of the U.S. influenza vaccine market?

What will be the CAGR of the influenza vaccine market in the United States?

How many people will be vaccinated with flu vaccines in the U.S. between 2018 and 2031?

What percentage of people in the United States get vaccinated against influenza?

What are the main flu vaccines available in the United States?

What are the key drivers of the influenza vaccine market in the United States?

What are the major barriers to the influenza vaccine market in the United States?

What is the reimbursement pattern in the influenza vaccine market in the United States?

What is the regulatory framework for the influenza vaccine market in the United States?

What are the key deals and agreements in the United States influenza vaccine market?

What are the upcoming flu vaccines that will significantly impact the market in the future?

Who are the main market participants? What is happening with them, what revenues do they generate from vaccines, and what are the current developments and scenarios?

Who are the new players? What are their events, clinical developments, platform technologies, phases, and current developments?

How is the market likely to develop in the future?

Contents

1. INTRODUCTION

2. RESEARCH METHODOLOGY

3. EXECUTIVE SUMMARY

4. UNITED STATES INFLUENZA VACCINES MARKET SIZE, INSIGHTS, ANALYSIS, AND FORECASTS (2018 - 2031)

5. UNITED STATES NUMBER OF PERSONS VACCINATED WITH INFLUENZA VACCINES (2018 - 2031)

5.1 Number of Children Vaccinated with Influenza Vaccines

5.2 Number of Adults Vaccinated with Influenza Vaccines

6. KEY MARKET GROWTH DRIVERS AND CHALLENGES OF THE UNITED STATES INFLUENZA VACCINES MARKET

6.1 Market Drivers

6.2 Market Challenges

7. UNITED STATES INFLUENZA VACCINES PRICING ANALYSIS, TRENDS AND INSIGHTS

8. UNITED STATES INFLUENZA VACCINES PRODUCTION, SUPPLY, AND ALLOCATION (BY COMPANIES), 2014 - 2022

9. UNITED STATES INFLUENZA VACCINES DISTRIBUTION AND DEMAND ANALYSIS 2010 - 2022

10. EFFECTIVENESS OF INFLUENZA VACCINES IN THE UNITED STATES, 2004 – 2022

11. RAPID DIAGNOSTIC TESTING FOR THE MANAGEMENT OF INFLUENZA

12. DISTRIBUTION CHANNEL AND TECHNIQUE DETAILED INSIGHTS OF

INFLUENZA VACCINATION IN THE UNITED STATES

13. REIMBURSEMENT ENVIRONMENT OF THE UNITED STATES INFLUENZA VACCINES MARKET

14. REGULATORY FRAMEWORK OF THE UNITED STATES INFLUENZA VACCINES MARKET

15. MAJOR DEALS AND AGREEMENT ACTIVITIES IN THE INFLUENZA VACCINES MARKET

15.1 Merger and Acquisitions

15.2 Collaboration Deals

15.3 Licensing Agreement

15.4 Exclusive Agreement

15.5 Distribution Agreement

16. PROMISING INFLUENZA VACCINES IN THE CLINICAL DEVELOPMENT

17. INFLUENZA VACCINES CLINICAL TRIAL INSIGHTS BY PHASE, COMPANY AND COUNTRY

17.1 Year 2022

17.2 Year 2021

17.3 Year 2020

18. COMPANY PROFILES

18.1 Sanofi Pasteur

18.1.1 Business Overview

18.1.2 Influenza Vaccines Portfolio

18.1.3 Influenza Vaccines Sales Value Analysis

18.1.4 Promising Influenza Vaccines in the Clinical Development

18.1.5 Recent Development

18.2 GlaxoSmithKline (GSK)

18.2.1 Business Overview

18.2.2 Influenza Vaccines Portfolio

18.2.3 Influenza Vaccines Sales Value Analysis

18.2.4 Recent Development

18.3 Seqirus

18.3.1 Business Overview

18.3.2 Influenza Vaccines Portfolios

18.3.3 Influenza Vaccines Sales Value Analysis

18.3.4 Promising Influenza Vaccines in the Clinical Development

18.3.5 Recent Development

18.4 AstraZeneca

18.4.1 Business Overview

18.4.2 Influenza Vaccines Portfolio

18.4.3 Influenza Vaccines Sales Value Analysis

18.4.4 Recent Development

19. EMERGING COMPANY PROFILES

19.1 Novavax

19.1.1 Business Overview

19.1.2 Promising Influenza Vaccines in the Clinical Development

19.1.3 Recent Development

19.2 BiondVax Pharmaceuticals Ltd.

19.2.1 Business Overview

19.2.2 Promising Influenza Vaccines in the Clinical Development

19.2.3 Recent Development

19.3 Medicago

19.3.1 Business Overview

19.3.2 Promising Influenza Vaccines in the Clinical Development

19.3.3 Recent Development

19.4 Moderna Inc

19.4.1 Business Overview

19.4.2 Promising Influenza Vaccines in the Clinical Development

19.4.3 Recent Development

19.5 Pneumagen

19.5.1 Business Overview

19.5.2 Promising Influenza Vaccines in the Clinical Development

19.5.3 Recent Development

19.6 Altimune

19.6.1 Business Overview

19.6.2 Promising Influenza Vaccines in the Clinical Development

19.6.3 Recent Development

19.7 Daiichi Sankyo

19.7.1 Business Overview

19.7.2 Promising Influenza Vaccines in the Clinical Development

19.7.3 Recent Development

19.8 FluGen

19.8.1 Business Overview

19.8.2 Promising Influenza Vaccines in the Clinical Development

19.8.3 Recent Development

19.9 Imutex

19.9.1 Business Overview

19.9.2 Promising Vaccines in the Clinical Development

19.9.3 Recent Development

19.10 EpiVax

19.10.1 Business Overview

19.10.2 Promising Influenza Vaccines in the Clinical Development

19.10.3 Recent Development

19.11 Versatope Therapeutics, Inc.

19.11.1 Business Overview

19.11.2 Promising Influenza Vaccines in the Clinical Development

19.11.3 Recent Development

20. APPENDIX

20.1 About DPI Research

20.2 Glossary of Terms

List Of Tables

LIST OF TABLES:

Table 7 1: United States Pediatric Influenza Vaccines Price, 2022 – 2023

Table 7 2: United States Adult Influenza Vaccines Price, 2022 – 2023

Table 8 1: United States Influenza Vaccines Production, Supply, and Allocation

Table 9 1: Total Percentage of Influenza Vaccines Released by Week, 2021 – 2022

Table 9 2: Total Percentage of Influenza Vaccines Released by Week, 2020 – 2021

Table 9 3: Total Percentage of Influenza Vaccines Released by Week, 2019 – 2020

Table 9 4: Total Percentage of Influenza Vaccines Released by Week, 2018 – 2019

Table 9 5: Total Percentage of Influenza Vaccines Released by Week, 2017 – 2018

Table 9 6: Total Percentage of Influenza Vaccines Released by Week, 2016 – 2017

Table 9 7: Total Percentage of Influenza Vaccines Released by Week, 2015 – 2016

Table 9 8: Total Percentage of Influenza Vaccines Released by Week, 2014 – 2015

Table 10 1: Adjusted Vaccine Effectiveness Estimates for Influenza Seasons, 2004 – 2021

Table 11 1: Influenza Virus Testing Methods

Table 12 1: Distribution of Influenza Vaccination

Table 14 1: United States Simplified Regulatory Pathway from Preclinical to the Marketing Authorization

Table 15 1: Merger & Acquisitions in the Influenza Vaccines Market

Table 15 2: Collaboration Deal in the Influenza Vaccines Market

Table 15 3: Licensing Agreement in the Influenza Vaccines Market

Table 15 4: Exclusive Agreement in the Influenza Vaccines Market

Table 15 5: Distribution Agreement in the Influenza Vaccines Market

Table 16 1: BiondVax Pharmaceuticals Ltd. – Clinical Trials

Table 18 1: Sanofi Pasteur Promising Influenza Vaccines in the Clinical Development

Table 18 2: Seqirus Promising Influenza Vaccines in the Clinical Development

Table 19 1: Novavax Promising Influenza Vaccines in the Clinical Development

Table 19 2: BiondVax Promising Influenza Vaccines in the Clinical Development

Table 19 3: Medicargo Promising Influenza Vaccines in the Clinical Development

Table 19 4: Moderna Promising Influenza Vaccines in the Clinical Development

Table 19 5: Pneumagen Promising Influenza Vaccines in the Clinical Development

Table 19 6: Altimmune Promising Influenza Vaccines in the Clinical Development

Table 19 7: Daiichi Sankyo Promising Influenza Vaccines in the Clinical Development

Table 19 8: FluGen Promising Influenza Vaccines in the Clinical Development

Table 19 9: Imutex Promising Influenza Vaccines in the Clinical Development

Table 19 10: EpiVax Promising Influenza Vaccines in the Clinical Development

Table 19 11: Versatope Therapeutics, Inc. Promising Influenza Vaccines in the Clinical Development

List Of Figures

LIST OF FIGURES:

Figure 2 1: United States Influenza Vaccines Market Size and Analysis (Million US\$),2018 – 2022

Figure 2 2: United States Influenza Vaccines Market Size and Forecast (Million US\$),2023 – 2031

Figure 3 1: United States Total Number of Individuals Vaccinated with Influenza Vaccines (Thousand), 2018 – 2022

Figure 3 2: United States Total Number of Individuals Vaccinated with Influenza Vaccines Forecast (Thousand), 2023 – 2031

Figure 3 3: United States Number of Children Vaccinated with Influenza Vaccines (Thousand),2018 – 2022

Figure 3 4: United States Number of Children Vaccinated with Influenza Vaccines Forecast (Thousand),2023 – 2031

Figure 3 5: United States Number of Adults Vaccinated with Influenza Vaccines (Thousand),2018 – 2022

Figure 3 6: United States Number of Adults Vaccinated with Influenza Vaccines Forecast (Thousand),2023 – 2031

Figure 7 1: United States Influenza Vaccine Doses Distributed, By Season (Million),2010 – 2022

Figure 10 1: United States Place of Influenza Vaccination for Children and Adults (Percent),2021 - 2022

Figure 16 1: Sanofi Pasteur Influenza Vaccines Net Sales Value (Million US\$),2018 – 2022

Figure 16 2: Sanofi Pasteur Influenza Vaccines Net Sales Value Forecast (Million US\$),2023 – 2031

Figure 16 3: GSK Influenza Vaccines Net Sales Value (Million US\$),2018 – 2022

Figure 16 4: GSK Influenza Vaccines Net Sales Value Forecast (Million US\$),2023 – 2031

Figure 16 5: Seqirus Influenza Vaccines Net Sales Value (Million US\$),2018 – 2022

Figure 16 6: Seqirus Influenza Vaccines Net Sales Value Forecast (Million US\$),2023 – 2031

Figure 16 7: AstraZeneca Influenza Vaccines Net Sales Value (Million US\$),2018 – 2022

Figure 16 8: AstraZeneca Influenza Vaccines Net Sales Value Forecast (Million US\$),2023 – 2031

I would like to order

Product name: United States Influenza Vaccines Market Size, Industry Trends, Share, Size, Growth, Opportunity and Forecast 2023-2031

Product link: <https://marketpublishers.com/r/U5B4B0F721A2EN.html>

Price: US\$ 1,990.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/U5B4B0F721A2EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

